DTaP vaccine - GlaxoSmithKline

Drug Profile

DTaP vaccine - GlaxoSmithKline

Alternative Names: Acelluvax DTP; Diphtheria tetanus-acellular pertussis vaccine - GlaxoSmithLine; Pertugen™; Triacelluvax™

Latest Information Update: 17 Mar 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 28 May 2002 Ventiv Health France will market Chiron's vaccines product line in France
  • 01 May 2000 Launched for Diphtheria in Italy (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top